drugset
drugset / Trial / NCT01121757

Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

NCT01121757 ↗

Phase 2 Terminated 11 enrolled Duke University Celgene Corporation · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the response and safety in subjects receiving the drugs lenalidomide and azacitidine when each drug is given by itself and when the drugs are taken together. This study is open for patients with relapsed or refractory follicular or marginal zone lymphoma.

Timeline

Start
2010-04
Primary completion
2013-03
Completion
2016-01

Outcome

Outcome not reported

Stopped: “The study closed temporarily in February 2012 pending analysis of samples collected. In October, 2012, Celgene requested closure of the study.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 75 mg/m2 Subcutaneous
Subject Lenalidomide Other / unclassified 15 mg Oral

Indications

follicular lymphoma marginal zone lymphoma